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Primary mitral regurgitation (MR) covers all etiologies in which in-
trinsic lesions affect one or several components of themitral valve appa-
ratus. Reduced incidence of rheumatic fever and increased lifespan in
industrialized countries have progressively changed the distribution of
etiologies, with degenerative MR now being the most common [1,2,3].
Echocardiography is the principal investigation andmust include an as-
sessment of severity, mechanisms, repairability, and consequences [4].
In chronic primary MR, the pathology of ≥1 of the components of the
valve (leaﬂets, chordae tendineae, papillary muscles, annulus) causes
valve incompetence with systolic regurgitation of blood from the left
ventricle (LV) to the left atrium. The stages of primary MR are: at risk
of (mild) MR, progressive (moderate) MR, asymptomatic severe MR,
and symptomatic severe MR [5]. According to 2012 European Guide-
lines on the management of valvular heart disease [6] the indications
for surgery in severe chronic primaryMR in the presence of atrial ﬁbril-
lation (AF), surgery should be considered in asymptomatic patients
with preserved LV function and new onset AF or pulmonary hyperten-
sion (systolic pulmonary pressure at rest N50 mmHg) (Class of recom-
mendation IIa Level of evidence C). The 2014 AHA/ACCGuideline for the
Management of Patients With Valvular Heart Disease [5] suggests that
mitral valve repair is reasonable for asymptomatic patients with
chronic severe non-rheumatic primary MR and preserved LV function
in whom there is a high likelihood of a successful and durable repair
with new onset of AF or resting pulmonary hypertension (pulmonary
artery systolic arterial pressure N 50mmHg) (Class of recommendation
IIa Level of evidence B). But what to do when the patients develop par-
oxysmal AF and have mild or moderate MR? The procedures to correct
MR have no place yet. The ideal approach for the treatment of AF is
rhythm control, but this is sometimes very hard to accomplish [7]. For
such procedures, complete isolation of all pulmonary veins (PVs) is cur-
rently widely accepted as the best endpoint.
This prospective, longitudinal study involved 158 patients without
MR or with mild to moderate MR, all of them having a history of symp-
tomatic paroxysmal AF (PAF). The study was piloted in agreement with
the Helsinki declaration and approved by the ethics committee of our
institution. All patients signed the informed consent term before inclu-
sion. This studywas conducted at theHospital e Clínica São Gonçalo, Rio
de Janeiro, Brazil. Patients were recruited from January 2011 till January
2015 from the Arrhythmias and Artiﬁcial Cardiac Pacing Service of thehttp://dx.doi.org/10.1016/j.ijcme.2016.11.006
2214-7624/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access artisame hospital. Enrolled patients met the following criteria: (i) a physi-
cally normal heart with an ejection fraction of N50% as measured by
echocardiography (Simpson's method), (ii) PAF (deﬁned as AF episodes
lasting b7 dayswith spontaneous termination) registered on ECGor 24-
h Holter monitoring, (iii) aged 18 to 80 years, (iv) estimated glomerular
ﬁltration rate (eGFR) of N60 mL/min/1.73 m2, calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eq. [8]
(without microalbuminuria), (v) absence of MR or mild to moderate
MR as deﬁned by the 2014 AHA/ACC Guideline for the Management of
Patients With Valvular Heart Disease [5], and (vi) the capacity to read,
comprehend and sign the informed consent form, and attend the
study. Patients with any of the following were excluded: (i) pregnancy;
(ii) unstable angina, myocardial infarction, transient ischemic attack or
strokewithin the preceding six months; (iii) renovascular abnormalities;
(iv) psychiatric disease; (v) allergy to ionic contrast medium; (vi) the in-
ability to bemonitored clinically after the procedure; (vii) a knownaddic-
tion to alcohol or drugs that affects the intellect; (viii) a serious health
condition that, in the investigator's opinion, may have adversely affected
the safety and/or efﬁcacy of the participant or the study; (ix) congestive
heart failure (symptoms of functional class II to IV heart failure on the
New York Heart Association scale); (x) a previous AF ablation procedure;
(xi) treatment with amiodarone.
The subjects were divided into 3 groups according to MR status: no
MR (n = 58), mild MR (n = 51), and moderate MR (n = 49). All of
them were followed until 18 months after PVI to assess the mainte-
nance of sinus rhythm. The primary endpoint of this study was a 30-s
recurrence of AF recorded by the 24-h-Holter monitoring. The blanking
period (the ﬁrst 3 months after ablation) was excluded from the analy-
sis [9], the evaluation of the patients at the ofﬁce and the 24-h-Holter
monitoring was evaluated at baseline and quarterly after the perfor-
mance of procedures forward. At the ﬁrst appearance of any symptoms
suggestive of AF, patients were instructed to seek an emergency service
and to be submitted to the ECG. The AF ablation procedure has been de-
scribed in detail previously [10]. All patients underwent complete PVI
using a three-dimensional mapping system (EnSite Velocity; St. Jude
Medical) without additional ablation lesion sets or lines. Patients still
in AF at the end of the procedure were converted to sinus rhythm by
cardioversion.
The results are expressed as a mean and standard deviation for nor-
mally distributed data and as median with interquartile range other-
wise. Comparisons between two-paired values were performed with
the paired t-test in cases of a Gaussian distribution and by theWilcoxon
test otherwise. For normality of distribution, D'Agostino-Pearson test
was used. Comparisons between more than two-paired values were
made by repeated-measures analysis of variance or by Kruskal–Wallis
analysis of variance as appropriate, complemented by the post-hoc
Tukey test. Categorical variables were compared with Fisher's exact
test. A two-tailed P-value b 0.05wasused as a criterion for statistical sig-
niﬁcance. Correlations between two variables were performed by
Pearson's chi-square test in case of a Gaussian distribution and with
the Spearman correlation test otherwise. Kaplan–Meier analysis was
performed to determine the probability of success, estimated as thecle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
Parameters No mitral
valve
regurgitation
Mild mitral
valve
regurgitation
Moderate
mitral
valve
regurgitation
Overall
P value
N 58 51 49 –
Age, years 63 ± 12 60 ± 15 67 ± 19 0.0780
Body mass index, kg/m2 29.0 ± 4.3 27.8 ± 4.8 27.5 ± 4.0 0.1697
Male sex (%) 45 (78%) 40 (71%) 30 (61%) 0.1821
White ethnicity (%) 40 (69%) 42 (82%) 37 (76%) 0.2701
Paroxysmal AF 58 (100%) 51 (100%) 49 (100%) 1.0000
Hypertension 46 (79%) 40 (71%) 33 (67%) 0.2955
Type 2 Diabetes Mellitus 22 (38%) 20 (39%) 25 (51%) 0.3367
Creatinine, mg/dL 1.00 ± 0.23 0.92 ± 0.38 0.95 ± 0.27 0.3665
eGFR, mL/min/1.73 m2 85.8 ± 17.4 90.3 ± 18.1 82.7 ± 19.2 0.1129
Albumin:creatinine ratio,
mg/g
14.0 ± 6.6 11.3 ± 8.0 12.7 ± 8.8 0.1990
Antihypertensive
ACE-inhibitors/ARB 46 (79%) 40 (71%) 33 (67%) 0.2955
Diuretics 50 (86%) 43 (84%) 36 (73%) 0.1986
DHP Ca++ channel
blockers
30 (52%) 28 (55%) 30 (61%) 0.6093
β-blockers 44 (76%) 42 (82%) 38 (78%) 0.7000
Mean 24-h ABPM, mmHg
Systolic 121.5 ± 4.0 120.1 ± 8.6 118.9 ± 11.3 0.2737
Diastolic 75.8 ± 5.1 77.0 ± 6.3 77.3 ± 3.2 0.2628
Values are expressed as mean ± SD; ABPM, ambulatory blood pressure measurements;
ACE, angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; DHP, dihydropyridine; eGFR, estimated glomerularﬁltration rate; PVI, pulmonary
veins isolation.
Fig. 1. Kaplan-Meier curves depicting recurrences of paroxysmal atrial ﬁbrillation (AF)
following pulmonary vein isolation (PVI) in patients without mitral regurgitation (MR)
(n= 58), with mild (n= 51) andmoderate (n= 49)MR during 18months of follow-up.
7Letter to the Editorpercentage of AF freedom. Differences in arrhythmia-free survival were
assessed with the log-rank test. Cox regression analysis was applied to
explore factors of AF recurrences. All statistical analyses were per-
formed using the program Graphpad Prism v 7.0 (Graphpad Software,
La Jolla, CA, USA).
The general features of the groups of patients are listed in Table 1
and echocardiographic parameters at baseline in Table 2. The mean
follow-up time for the patients without MR, mild MR, and moderate
MR presenting AF recurrence was 16 ± 3, 14 ± 4, and 11 ± 5 months,
respectively (P b 0.05 for all the comparisons between groups).Table 2
Echocardiographic parameters at baseline.
Parameters No mitral valve regurgitation
(n = 58)
Mild mi
(n = 51
Indexed left atrial volume (mL/m2) 31.9 ± 4.3 32.4 ±
IST (mm) 9.0 ± 2.5 9.3 ± 2
LVPWT (mm) 9.8 ± 1.6 10.0 ±
LVEF, Simpson (%) 68.2 ± 6.5 66.8 ±
LVEDD (mm) 44.8 ± 5.0 46.2 ±
LVESD (mm) 33.2 ± 6.4 33.8 ±
LV mass index (g/m2) 90.4 ± 12.9 93.6 ±
Values are expressed as mean ± SD; LV, left ventricular; LVEDD, left ventricular end-diastolic d
eter; LVPWT, left ventricular posterior wall thickness.
Table 3
Hazard ratio for AF recurrence between the absence and the presence of mild and moderate m
AF recurrence Hazard ratio
Mild regurgitation vs. no regurgitation 2.658
Moderate regurgitation vs. no regurgitation 4.286
Moderate regurgitation vs.mild regurgitation 1.891
AF, atrial ﬁbrillation; PVI, pulmonary veins isolation.During 18months of the follow-up period, AF recurrencewas higher
in moderate MR patients underwent PVI than in those ones with mild
MR or without MR, hazard ratio [HR], 95% conﬁdence interval [CI] and
P value by Log-rank test, are showed at Table 3. Therewas difference re-
lated to AF reappearance in the comparison between absence (70.7%
freedom from AF) and presence of mild (37.3% freedom from AF) to
moderate (22.4% freedom from AF) MR during the 18 months of
follow-up after PVI, by Log-rank test (P b 0.0001), Fig. 1.
We believe that during follow-up, AF recurrence was higher in the
moderateMR patients who underwent PVI than in the other groups be-
cause of the major mechanical problem in those mitral valves, generat-
ing an augmented pressure and a greater stress into the left atrium,
perpetuating the vicious AF cycle, and worsening the recurrence rate.
The presence of AF hampers measurement of LV ejection fraction be-
cause of tachycardia and beat-to-beat (i.e., R-to-R) LV ﬁlling variability.
Ourmeasurements could have been less precise becausewe did not use
a three-dimensional single-beat ultrasound system.
Due to the largest AF recurrence rates among patients with mild to
moderate MR in comparison with patients without MR, we shouldtral valve regurgitation
)
Moderate mitral valve regurgitation
(n = 49)
Overall P
value
6.5 34.1 ± 4.9 0.0882
.0 9.2 ± 2.3 0.7829
1.7 9.8 ± 1.5 0.7647
5.9 67.0 ± 5.4 0.4155
4.5 46.0 ± 6.1 0.3161
4.9 35.3 ± 4.0 0.1153
14.0 95.0 ± 18.7 0.2765
iameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diam-
itral valve regurgitation after PVI, evaluated by Log-rank test.
95% Conﬁdence Interval P value
1.506–4.693 0.0005
2.456–7.480 b0.0001
1.169–3.060 0.0044
8 Letter to the Editorthink about to perform the surgical valve repair and surgical AF ablation
procedure rather than simply perform the PVI.
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